KDL partner, Immunovia, illustrates their platform technology and the first test IMMray PanCan-d for early detection of pancreatic cancer.

Published on Jan 13, 2016

IMMray™ PanCan–d is the first blood-based test for early and specific (differential) diagnosis, providing clinicians with actionable information. Immunovia has defined a clinically relevant condensed panel of serum biomarkers (a biomarker signature) associated with pancreatic adenocarcinoma. This biomarker panel can be used for differential diagnosis at an early stage of the cancer. The test is suitable for screening risk-groups as well as investigating patients with suspected symptoms.